Swiss TPH

Daubenberger CA (2010) Gene-expression analysis for prediction of RTS,S-induced protection in humans. Expert Rev Vaccines 9, 465-469. PM:20450320

Dujardin JC, Herrera S, do R, V, Arevalo J, Boelaert M, Carrasco HJ, Correa-Oliveira R, Garcia L, Gotuzzo E, Gyorkos TW, Kalergis AM, Kouri G, Larraga V, Lutumba P, Macias Garcia MA, Manrique-Saide PC, Modabber F, Nieto A, Pluschke G, Robello C, Rojas de AA, Rumbo M, Santos Preciado JI, Sundar S, Torres J, Torrico F, Van der Stuyft P, Victoir K & Olesen OF (2010) Research priorities for neglected infectious diseases in Latin America and the Caribbean region. PLoS Negl Trop Dis 4, e780. PM:21049009

Kopp N, Diaz D, Amacker M, Odongo DO, Beier K, Nitsch C, Bishop RP & Daubenberger CA (2010) Identification of a synthetic peptide inducing cross-reactive antibodies binding to Rhipicephalus (Boophilus) decoloratus, Rhipicephalus (Boophilus) microplus, Hyalomma anatolicum anatolicum and Rhipicephalus appendiculatus BM86 homologues. Vaccine 28, 261-269. PM:19808026

Oberli MA, Tamborrini M, Tsai YH, Werz DB, Horlacher T, Adibekian A, Gauss D, Möller HM, Pluschke G & Seeberger PH (2010) Molecular analysis of carbohydrate-antibody interactions: case study using a Bacillus anthracis tetrasaccharide. J Am Chem Soc 132, 10239-10241. PM:20614885

Pidot SJ, Asiedu K, Käser M, Fyfe JA & Stinear TP (2010) Mycobacterium ulcerans and other mycolactone-producing mycobacteria should be considered a single species. PLoS Negl Trop Dis 4, e663. PM:20668542

Pidot SJ, Porter JL, Marsollier L, Chauty A, Migot-Nabias F, Badaut C, Benard A, Ruf MT, Seemann T, Johnson PD, Davies JK, Jenkin GA, Pluschke G & Stinear TP (2010) Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis 4, e872. PM:21072233

Pluschke G & Tamborrini M (2010) Virosomal technology in malaria vaccine development. Future Virol 5, 247-250.

Racloz VN & Luiz SJ (2010) The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 10, 175. PM:20565757

Röltgen K, Qi W, Ruf MT, Mensah-Quainoo E, Pidot SJ, Seemann T, Stinear TP, Käser M, Yeboah-Manu D & Pluschke G (2010) Single nucleotide polymorphism typing of Mycobacterium ulcerans reveals focal transmission of buruli ulcer in a highly endemic region of Ghana. PLoS Negl Trop Dis 4, e751. PM:20652033

Tamborrini M, Holzer M, Seeberger PH, Schürch N & Pluschke G (2010) Anthrax spore detection by a Luminex assay based on monoclonal antibodies recognizing anthrose-containing oligosaccharides. Clin Vaccine Immunol 17, 1446-1451. PM:20660139

Tamborrini M, Liu X, Mugasa JP, Kwon YU, Kamena F, Seeberger PH & Pluschke G (2010) Synthetic glycosylphosphatidylinositol microarray reveals differential antibody levels and fine specificities in children with mild and severe malaria. Bioorg Med Chem 18, 3747-3752. PM:20471845

Braxmeier S, Hellmann M, Beck A, Umboock A, Pluschke G, Junghanss T & Weinlaeder H (2009) Phase change material for thermotherapy of Buruli ulcer: modelling as an aid to implementation. J Med Eng Technol 7, 559-566. PM:19591051

Huygen K, Adjei O, Affolabi D, Bretzel G, Demangel C, Fleischer B, Johnson RC, Pedrosa J, Phanzu DM, Phillips RO, Pluschke G, Siegmund V, Singh M, van der Werf TS, Wansbrough-Jones M & Portaels F (2009) Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol 198, 69-77. PM:19198877

Junghanss T, Um BA, Vogel M, Schuette D, Weinlaeder H & Pluschke G (2009) Phase change material for thermotherapy of Buruli Ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis 3, e380. Fulltext

Käser M, Gutmann O, Hauser J, Stinear T, Cole S, Yeboah-Manu D, Dernick G, Certa U & Pluschke G (2009) Lack of insertional-deletional polymorphism in a collection of Mycobacterium ulcerans isolates from Ghanaian Buruli ulcer patients. J Clin Microbiol 47, 3640-3646. PM:19726605

Käser M, Hauser J & Pluschke G (2009) Single nucleotide polymorphisms on the road to strain differentiation in Mycobacterium ulcerans. J Clin Microbiol 47, 3647-3652. PM:19726608

Käser M, Hauser J, Small P & Pluschke G (2009) Large sequence polymorphisms unveil the phylogenetic relationship of environmental and pathogenic mycobacteria related to Mycobacterium ulcerans. Appl Environ Microbiol 75, 5667-5675. PM:19592526

Käser M, Ruf MT, Hauser J, Marsollier L & Pluschke G (2009) Optimized method for preparation of DNA from pathogenic and environmental mycobacteria. Appl Environ Microbiol 75, 414-418. PM:19047396

Leimkugel J, Racloz L, Da Silva J & Pluschke G (2009) Global review of meningococcal disease. A shifting etiology. J Bacteriol Res 1, 6-18.

Qi W, Käser M, Röltgen K, Yeboah-Manu D & Pluschke G (2009) Genomic diversity and evolution of Mycobacterium ulcerans revealed by next-generation sequencing. PloS Pathogens 5, 1-14. Fulltext

Schütte D & Pluschke G (2009) Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin Biol Ther 9, 187-200. PM:19236249

Schütte D, Umboock A & Pluschke G (2009) Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br J Dermatol 160, 273-283. PM:19016694

Tamborrini M, Mueller MS, Stoffel SA, Westerfeld N, Vogel D, Boato F, Zurbriggen R, Robinson JA & Pluschke G (2009) Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine. Malar J 8, 314. PM:20042100

Tamborrini M, Oberli MA, Werz DB, Schurch N, Frey J, Seeberger PH & Pluschke G (2009) Immuno-detection of anthrose containing tetrasaccharide in the exosporium of Bacillus anthracis and Bacillus cereus strains. J Appl Microbiol 106, 1618-1628. PM:19226390

Treeck M, Tamborrini M, Daubenberger CA, Gilberger TW & Voss TS (2009) Caught in action: mechanistic insights into antibody-mediated inhibition of Plasmodium merozoite invasion. Trends Parasitol 25, 494-497. PM:19734093

Antonio M, Dada-Adegbola H, Biney E, Awine T, O'Callaghan J, Pflüger V, Enwere G, Okoko B, Oluwalana C, Vaughan A, Zaman SM, Pluschke G, Greenwood BM, Cutts F & Adegbola RA (2008) Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine.  BMC Infect Dis 8, 81. Fulltext

Daubenberger C, Pluschke G, Zurbriggen R & Westerfeld N (2008) Development of influenza virosome-based synthetic malaria vaccines. Expert Opin Drug Discov 3, 415-423.

Huber CA, Ruf MT, Pluschke G & Kaeser M (2008) Independent loss of immunogenic proteins in Mycobacterium ulcerans suggests immune evasion. Clin Vaccine Immunol 15, 598-606. Fulltext

Kamena F, Tamborrini M, Liu X, Kwon YU, Thompson F, Pluschke G & Seeberger PH (2008) Synthetic GPI array to study antitoxic malaria response. Nat Chem Biol 4, 238-240. PM:18311131

Käser M & Pluschke G (2008) Differential gene repertoire in Mycobacterium ulcerans identifies candidate genes for patho-adaptation. PLoS Negl Trop Dis 2, e353. Fulltext

Mensah-Quainoo E, Yeboah-Manu D, Asebi C, Patafuor F, Ofori-Adjei D, Junghanss T & Pluschke G (2008) Diagnosis of Mycobacterium ulcerans infection (Buruli ulcer) at a treatment centre in Ghana: a retrospective analysis of laboratory results of clinically diagnosed cases. Trop Med Int Health 13, 191-198. PM:18304265

Okitsu SL, Mueller MS, Amacker M, Vogel D, Robinson JA, Zurbriggen R & Pluschke G (2007) Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology. Human Vaccines 4, 106-114. PM:18382133

Peduzzi E, Westerfeld N, Zurbriggen R, Pluschke G & Daubenberger CA (2008) Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Clin Immunol 127, 188-197. PM:18337175

Sie A, Pflüger V, Coulibaly B, Dangy JP, Kapaun A, Junghanss T, Pluschke G & Leimkugel J (2008) ST2859 serogroup A meningococcal meningitis outbreak in Nouna Health District, Burkina Faso: a prospective study. Trop Med Int Health 13, 861-868. PM:18384478

Tanghe A, Dangy JP, Pluschke G & Huygen K (2008) Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting. PLoS Negl Trop Dis 2, e199. Fulltext

Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, Poulton I, Correa S, Hutchings C, Berthoud T, Dunachie S, Andrews L, Williams JL, Sinden R, Gilbert SC, Pluschke G, Zurbriggen R & Hill AV (2008) Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 3, e1493. Fulltext

Daubenberger CA (2007) TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr Opin Mol Ther 9, 45-52. PM:17330401

Daubenberger CA, Spirig R, Patarroyo ME, Pluschke G (2007) Flow cytometric analysis on cross-reactivity of human-specific CD monoclonal antibodies with splenocytes of Aotus nancymaae, a non-human primate model for biomedical research. Vet Immunol Immunopathol 119, 14-20. PM:17644187

Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, Schroller S, Vounatsou P, Mueller MM, Tanner M, & Zurbriggen R (2007) A randomized placebo-controlled phase ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS ONE. 2, e1018. Fulltext

Hilty M, Käser M, Zinsstag J, Stinear T, Pluschke G (2007 May ) Analysis of the Mycobacterium ulcerans genome sequence reveals new loci for variable number tandem repeats (VNTR) typing. Microbiology 153, 1483-1487. Fulltext 

Jefferies JM, Johnston CH, Kirkham LA, Cowan GJ, Ross KS, Smith A, Clarke SC, Brueggemann AB, George RC, Pichon B, Pluschke G, Pfluger V & Mitchell TJ (2007) Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks. J Infect Dis 196, 936-944. PM:17703426

Käser M, Rondini S, Naegeli M, Stinear T, Portaels F, Certa U & Pluschke G (2007) Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans. BMC Evol Biol 7, 177. Fulltext

Leimkugel J, Forgor AA, Dangy JP, Pfluger V, Gagneux S, Hodgson A, Pluschke G (2007) Genetic diversification of Neisseria meningitidis during waves of colonization and disease in the meningitis belt of sub-Saharan Africa. Vaccine 25, A18-A23. PM:17531357

Leimkugel J, Hodgson A, Forgor AA, Pfluger V, Dangy JP, Smith T, Achtman M, Gagneux S, Pluschke G (2007) Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in Northern Ghana. PLoS Med 4, e101. Fulltext 

Odongo D, Kamau L, Skilton R, Mwaura S, Nitsch C, Musoke A, Taracha E, Daubenberger C, Bishop R (2007) Vaccination of cattle with TickGARD induces cross-reactive antibodies binding to conserved linear peptides of Bm86 homologues in Boophilus decoloratus. Vaccine 25, 1287-1296. PM:17070625

Okitsu SL, Boato F, Mueller MS, Li DB, Vogel D, Westerfeld N, Zurbriggen R, Robinson JA & Pluschke G (2007) Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47kDa fragment both in sporozoites and merozoites. Peptides 28, 2051-2060. PM:17875342

Okitsu SL, Kienzl U, Moehle K, Silvie O, Peduzzi E, Mueller MS, Sauerwein RW, Matile H, Zurbriggen R, Mazier D, Robinson JA, Pluschke G (2007) Structure-activity-based design of a synthetic malaria Peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem Biol 14, 577-587. PM:17524988

Okitsu SL, Mueller MS, Amacker M, Vogel D, Westerfeld N, Robinson JA, Zurbriggen R & Pluschke G (2007) Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology. Hum Vaccin 4, 106-14. PM:18382133

Okitsu SL, Silvie O, Westerfeld N, Curcic M, Kammer AR, Mueller MS, Sauerwein RW, Robinson JA, Genton B, Mazier D, Zurbriggen R & Pluschke G (2007) A virosomal malaria Peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS One 2, e1278. Fulltext

Peduzzi E, Groeper C, Schütte D, Zajac P, Rondini S, Mensah-Quainoo E, Spagnoli GC, Pluschke G, Daubenberger CA (2007) Local activation of the innate immune system in Buruli ulcer lesions. J Invest Dermatol 127, 638-645. Fulltext 

Rondini S, Käser M, Stinear T, Tessier M, Mangold C, Dernick G, Naegeli M, Portaels F, Certa U, Pluschke G (2007) Ongoing genome reduction in Mycobacterium ulcerans. Emerg Infect Dis 13, 1008-1015. PM:18214172

Schütte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P & Pluschke G (2007) Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 1, e2. Fulltext

Diaz D, Dobeli H, Yeboah-Manu D, Mensah-Quainoo E, Friedlein A, Soder N, Rondini S, Bodmer T & Pluschke G (2006) Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol 13, 1314-1321.

Hilty M, Yeboah-Manu D, Boakye D, Mensah-Quainoo E, Rondini S, Schelling E, Ofori-Adjei D, Portaels F, Zinsstag J & Pluschke G (2006) Genetic diversity in mycobacterium ulcerans isolates from Ghana revealed by a newly identified locus containing a variable number of tandem repeats. J Bacteriol 188, 1462-1465. http://dx.doi.org/10.1128/JB.188.4.1462-1465.2006

Hilty M, Yeboah-Manu D, Boakye D, Mensah-Quainoo E, Rondini S, Schelling E, Ofori-Adjei D, Portaels F, Zinsstag J, Pluschke G (2006 Feb ) Genetic diversity in mycobacterium ulcerans isolates from Ghana revealed by a newly identified locus containing a variable number of tandem repeats. J Bacteriol 188, 1462-1465. dx.doi.org/10.1128/JB.188.4.1462-1465.2006

James S, Moehle K, Renard A, Mueller MS, Vogel D, Zurbriggen R, Pluschke G, Robinson JA (2006 Dec ) Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1. Chembiochem 7, 1943-1950.

Liu X, Siegrist S, Amacker M, Zurbriggen R, Pluschke G, Seeberger PH (2006) Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate. ACS Chem Biol 1, 161-164.

Rondini S, Horsfield C, Mensah-Quainoo E, Junghanss T, Lucas S, Pluschke G (2006) Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol 208, 119-128. dx.doi.org/10.1002/path.1864

Rondini S, Mensah-Quainoo E, Junghanss T, Pluschke G (2006 Aug 23 ) What does detection of Mycobacterium ulcerans DNA in the margin of an excised Buruli ulcer lesion tell us?. J Clin Microbiol 44, 4273-4275. jcm.asm.org/cgi/reprint/JCM.00970-06v1?view=long&pmid=16928966

Tamborrini M, Werz DB, Frey J, Pluschke G, Seeberger PH (2006 Aug 17 ) Anti-Carbohydrate Antibodies for the Detection of Anthrax Spores. Angew Chem Int Ed Engl 45, 6581-6582. www3.interscience.wiley.com/cgi-bin/fulltext/112752113/PDFSTART

Westerfeld N, Pluschke G, Zurbriggen R (2006 Oct ) Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes. Wien Klin Wochenschr 118, 50-57.

Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, Asante-Poku A, Pluschke G, Daubenberger C (2006) Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 79, 1150-1156. www.jleukbio.org/cgi/rapidpdf/jlb.1005581v1